InMed Depreciation And Amortization vs Selling General Administrative Analysis

INM Stock

USD 4.97 0.17 3.54%

InMed Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating InMed Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether InMed Pharmaceuticals is a good investment. Please check the relationship between InMed Pharmaceuticals Depreciation And Amortization and its Selling General Administrative accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

Depreciation And Amortization vs Selling General Administrative

Depreciation And Amortization vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of InMed Pharmaceuticals Depreciation And Amortization account and Selling General Administrative. At this time, the significance of the direction appears to have almost no relationship.

The correlation between InMed Pharmaceuticals' Depreciation And Amortization and Selling General Administrative is 0.11. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of InMed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of InMed Pharmaceuticals' Depreciation And Amortization and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of InMed Pharmaceuticals are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Depreciation And Amortization i.e., InMed Pharmaceuticals' Depreciation And Amortization and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.11

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Selling General Administrative

Most indicators from InMed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 5th of January 2025, Issuance Of Capital Stock is likely to grow to about 8.5 M, while Enterprise Value Over EBITDA is likely to drop (2.12).

	2024	2025 (projected)
Interest Expense	86.5K	153.3K
Depreciation And Amortization	544.1K	284.9K

Interest Expense Depreciation And Amortization

InMed Pharmaceuticals fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Current Deferred Revenue	Short Term Debt	Good Will
Total Assets		0.66	0.99	0.29	-0.9	-0.62	0.76	0.95	0.4	-0.12	0.9	0.48	0.43	0.45	0.69	-0.05	-0.23	-0.17	0.64	0.99	0.29	0.44	0.52	-0.28	0.52	0.09
Total Current Liabilities	0.66		0.52	0.49	-0.37	-0.89	0.77	0.48	0.72	-0.12	0.36	0.57	0.54	0.52	0.36	-0.25	-0.2	0.29	0.99	0.56	0.57	0.67	0.84	-0.61	0.81	0.1
Total Stockholder Equity	0.99	0.52		0.2	-0.94	-0.5	0.69	0.97	0.28	-0.11	0.94	0.4	0.34	0.38	0.69	-0.01	-0.23	-0.27	0.5	0.99	0.2	0.33	0.41	-0.21	0.4	0.08
Property Plant And Equipment Net	0.29	0.49	0.2		0.07	-0.39	0.31	0.04	0.79	0.69	-0.01	0.75	0.6	0.56	0.37	0.09	-0.06	0.43	0.54	0.15	0.1	0.47	0.22	-0.06	0.57	-0.66
Net Debt	-0.9	-0.37	-0.94	0.07		0.36	-0.62	-0.98	0.01	0.25	-0.98	-0.12	-0.09	-0.15	-0.52	0.13	0.21	0.43	-0.33	-0.95	-0.06	-0.1	-0.35	0.23	-0.17	-0.23
Retained Earnings	-0.62	-0.89	-0.5	-0.39	0.36		-0.54	-0.47	-0.77	0.33	-0.32	-0.73	-0.73	-0.76	-0.29	0.15	0.36	-0.43	-0.91	-0.53	-0.77	-0.79	-0.71	0.5	-0.89	-0.31
Accounts Payable	0.76	0.77	0.69	0.31	-0.62	-0.54		0.66	0.29	0.0	0.68	0.26	0.19	0.14	0.66	-0.17	-0.01	-0.29	0.73	0.74	0.09	0.3	0.86	-0.38	0.39	0.03
Cash	0.95	0.48	0.97	0.04	-0.98	-0.47	0.66		0.15	-0.26	0.96	0.27	0.26	0.29	0.59	-0.11	-0.19	-0.34	0.45	0.98	0.18	0.27	0.39	-0.22	0.3	0.22
Non Current Assets Total	0.4	0.72	0.28	0.79	0.01	-0.77	0.29	0.15		0.16	-0.01	0.87	0.83	0.82	0.28	0.14	-0.22	0.67	0.78	0.25	0.69	0.84	0.36	-0.26	0.93	-0.19
Non Currrent Assets Other	-0.12	-0.12	-0.11	0.69	0.25	0.33	0.0	-0.26	0.16		-0.15	0.14	-0.1	-0.09	0.1	0.08	0.05	0.09	-0.13	-0.17	-0.56	-0.27	-0.21	0.09	-0.11	-0.91
Cash And Short Term Investments	0.9	0.36	0.94	-0.01	-0.98	-0.32	0.68	0.96	-0.01	-0.15		0.14	0.09	0.13	0.62	-0.09	-0.16	-0.47	0.31	0.95	-0.01	0.09	0.39	-0.18	0.14	0.19
Net Receivables	0.48	0.57	0.4	0.75	-0.12	-0.73	0.26	0.27	0.87	0.14	0.14		0.91	0.95	0.44	0.22	-0.31	0.49	0.65	0.35	0.53	0.78	0.29	-0.02	0.81	-0.17
Common Stock Shares Outstanding	0.43	0.54	0.34	0.6	-0.09	-0.73	0.19	0.26	0.83	-0.1	0.09	0.91		0.93	0.45	0.13	-0.05	0.47	0.65	0.31	0.65	0.91	0.25	0.11	0.76	0.02
Short Term Investments	0.45	0.52	0.38	0.56	-0.15	-0.76	0.14	0.29	0.82	-0.09	0.13	0.95	0.93		0.32	0.17	-0.41	0.51	0.6	0.34	0.67	0.79	0.25	-0.04	0.8	0.03
Non Current Liabilities Total	0.69	0.36	0.69	0.37	-0.52	-0.29	0.66	0.59	0.28	0.1	0.62	0.44	0.45	0.32		0.15	0.28	-0.29	0.4	0.68	0.02	0.43	0.37	0.26	0.25	-0.14
Inventory	-0.05	-0.25	-0.01	0.09	0.13	0.15	-0.17	-0.11	0.14	0.08	-0.09	0.22	0.13	0.17	0.15		-0.07	-0.13	-0.21	-0.07	0.12	0.17	-0.27	0.54	0.16	-0.07
Other Current Assets	-0.23	-0.2	-0.23	-0.06	0.21	0.36	-0.01	-0.19	-0.22	0.05	-0.16	-0.31	-0.05	-0.41	0.28	-0.07		-0.25	-0.13	-0.2	-0.29	0.07	-0.16	0.54	-0.39	-0.07
Other Stockholder Equity	-0.17	0.29	-0.27	0.43	0.43	-0.43	-0.29	-0.34	0.67	0.09	-0.47	0.49	0.47	0.51	-0.29	-0.13	-0.25		0.33	-0.29	0.58	0.47	-0.06	-0.37	0.6	-0.09
Total Liab	0.64	0.99	0.5	0.54	-0.33	-0.91	0.73	0.45	0.78	-0.13	0.31	0.65	0.65	0.6	0.4	-0.21	-0.13	0.33		0.53	0.62	0.77	0.8	-0.51	0.84	0.1
Total Current Assets	0.99	0.56	0.99	0.15	-0.95	-0.53	0.74	0.98	0.25	-0.17	0.95	0.35	0.31	0.34	0.68	-0.07	-0.2	-0.29	0.53		0.21	0.33	0.48	-0.25	0.39	0.14
Intangible Assets	0.29	0.57	0.2	0.1	-0.06	-0.77	0.09	0.18	0.69	-0.56	-0.01	0.53	0.65	0.67	0.02	0.12	-0.29	0.58	0.62	0.21		0.81	0.31	-0.32	0.83	0.48
Short Long Term Debt Total	0.44	0.67	0.33	0.47	-0.1	-0.79	0.3	0.27	0.84	-0.27	0.09	0.78	0.91	0.79	0.43	0.17	0.07	0.47	0.77	0.33	0.81		0.37	-0.02	0.84	0.19
Other Current Liab	0.52	0.84	0.41	0.22	-0.35	-0.71	0.86	0.39	0.36	-0.21	0.39	0.29	0.25	0.25	0.37	-0.27	-0.16	-0.06	0.8	0.48	0.31	0.37		-0.53	0.49	0.27
Current Deferred Revenue	-0.28	-0.61	-0.21	-0.06	0.23	0.5	-0.38	-0.22	-0.26	0.09	-0.18	-0.02	0.11	-0.04	0.26	0.54	0.54	-0.37	-0.51	-0.25	-0.32	-0.02	-0.53		-0.42	-0.14
Short Term Debt	0.52	0.81	0.4	0.57	-0.17	-0.89	0.39	0.3	0.93	-0.11	0.14	0.81	0.76	0.8	0.25	0.16	-0.39	0.6	0.84	0.39	0.83	0.84	0.49	-0.42		0.08
Good Will	0.09	0.1	0.08	-0.66	-0.23	-0.31	0.03	0.22	-0.19	-0.91	0.19	-0.17	0.02	0.03	-0.14	-0.07	-0.07	-0.09	0.1	0.14	0.48	0.19	0.27	-0.14	0.08

Click cells to compare fundamentals

InMed Pharmaceuticals Account Relationship Matchups

InMed Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	9.8M	12.8M	14.1M	11.8M	13.6M	14.3M
Total Current Liabilities	2.2M	3.3M	2.0M	2.0M	2.3M	2.4M
Total Stockholder Equity	7.4M	9.1M	12.1M	9.2M	10.6M	11.1M
Property Plant And Equipment Net	326.6K	904.3K	723.4K	1.2M	1.4M	1.5M
Net Debt	(7.1M)	(5.4M)	(8.5M)	(5.6M)	(5.0M)	(4.8M)
Retained Earnings	(74.9M)	(93.5M)	(101.4M)	(109.1M)	(98.2M)	(93.3M)
Accounts Payable	775.1K	1.2M	544.2K	626.2K	720.1K	615.9K
Cash	7.4M	6.2M	8.9M	6.6M	7.6M	7.9M
Non Current Assets Total	1.4M	3.2M	2.8M	3.1M	3.6M	3.8M
Non Currrent Assets Other	14.7K	176.6K	104.9K	100K	90K	166.4K
Cash And Short Term Investments	7.4M	6.2M	8.9M	6.6M	7.6M	3.9M
Net Receivables	11.9K	88.0K	260.4K	352.8K	317.6K	333.4K
Common Stock Shares Outstanding	270K	560.8K	2.4M	7.6M	8.7M	9.2M
Short Term Investments	46.5K	44.8K	44.4M	43.1M	49.5M	52.0M
Liabilities And Stockholders Equity	9.8M	12.8M	14.1M	11.8M	13.6M	14.3M
Non Current Liabilities Total	189.3K	389.5K	16.0K	644.9K	741.6K	778.7K
Inventory	(955.8M)	2.5M	1.6M	1.2M	1.1M	1.2M
Other Current Assets	956.8K	842.0K	(8.9B)	477.7K	430.0K	451.5K
Other Stockholder Equity	21.5M	31.7M	35.7M	35.4M	31.8M	33.4M
Total Liab	2.4M	3.7M	2.0M	2.6M	3.0M	3.2M
Total Current Assets	8.4M	9.6M	11.3M	8.7M	10.0M	10.5M
Intangible Assets	1.1M	2.1M	1.9M	1.8M	2.1M	2.2M
Short Long Term Debt Total	269.8K	793.8K	391.7K	962.7K	1.1M	1.2M
Other Current Liab	1.4M	1.7M	1.1M	1.0M	1.2M	612.0K
Short Term Debt	80.5K	404.3K	375.7K	317.8K	365.5K	383.7K
Common Stock	60.6M	70.7M	77.6M	82.8M	95.2M	53.5M
Net Tangible Assets	6.5M	6.3M	7.0M	10.1M	9.1M	9.1M
Net Invested Capital	7.4M	9.1M	12.1M	9.2M	8.3M	8.4M
Net Working Capital	6.2M	6.3M	9.3M	6.7M	6.0M	7.1M
Property Plant Equipment	549.9K	326.6K	904.3K	723.4K	831.9K	873.5K
Capital Stock	60.6M	70.7M	77.6M	82.8M	95.2M	72.3M
Capital Lease Obligations	269.8K	793.8K	391.7K	962.7K	1.1M	627.0K
Property Plant And Equipment Gross	326.6K	1.4M	1.6M	2.6M	3.0M	3.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:

How To Invest In InMed

Details

Is InMed Stock a good investment?

Details

What is InMed Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

230.4

Revenue Per Share

0.603

Quarterly Revenue Growth

(0.45)

Return On Assets

(0.39)

Return On Equity

(0.72)

The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

InMed Depreciation And Amortization vs Selling General Administrative Analysis

Depreciation And Amortization vs Selling General Administrative

Depreciation And Amortization vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Depreciation And Amortization

Selling General Administrative

InMed Pharmaceuticals fundamental ratios Correlations

InMed Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

InMed Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Total Current Assets	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash
Cash	+ 0.97	Total Stockholder Equity

Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Total Current Assets	- 0.95	Net Debt
Net Debt	- 0.94	Total Stockholder Equity
Good Will	- 0.91	Non Currrent Assets Other
Total Liab	- 0.91	Retained Earnings